Dacomitinib/Dacomitinib: a new oral anti-cancer drug launched in China

Dacomitinib/Dacomitinib (Dacomitinib), a newly launched anti-cancer drug in China, is indeed available to patients in oral form. As a new member of the tyrosine kinase inhibitor family, dacomitinib has shown significant efficacy in the treatment of EGFR mutation-positive advanced non-small cell lung cancer. By effectively blocking the proliferation and spread of cancer cells, it has won patients a longer survival period and greatly improved their quality of life, becoming a major breakthrough in the field of lung cancer treatment.

The launch of dacomitinib in China undoubtedly brings hope to the majority of patients. Compared with traditional injection or intravenous infusion treatment methods, the use of oral drugs is undoubtedly more convenient. Patients can easily complete the treatment process at home, eliminating the trouble of frequent trips to the hospital. At the same time, the flexibility of oral drug dosage adjustment also provides doctors with more treatment options, making personalized treatment plans possible. It is worth mentioning that although dacomitinib is effective, its possible side effects cannot be ignored. Patients may experience nausea, vomiting, diarrhea and other uncomfortable symptoms during use. Therefore, when taking dacomitinib, patients should strictly follow the doctor's instructions to ensure the safety and effectiveness of the drug.

Patients need to clearly understand the medication instructions for dacomitinib. The usual recommended dose is 45 mg taken orally once daily. In order to maintain stable blood drug concentrations, patients should try to take the drug at the same time every day, and can choose to take it with food or on an empty stomach. However, the specific medication regimen and course of treatment need to be determined based on the patient's individual situation and the doctor's instructions.